Literature DB >> 3191817

Developmental changes of caffeine elimination in infancy.

G Pons1, O Carrier, M O Richard, E Rey, P d'Athis, C Moran, J Badoual, G Olive.   

Abstract

Five neonates (4 premature) and 16 infants (6 prematurely born), 15-588 days old, received caffeine as citrate salt for apnea. Plasma samples were collected 0, 2, 4, 6 h after a dose and before the next scheduled one. Patients 8 and 9 were serially studied. Caffeine plasma concentrations were determined using HPLC. The caffeine elimination half-life and clearance varied linearly with gestational age and exponentially with postnatal age, the plateau being reached during the second trimester of life. Dose regimen guidelines as a function of postnatal age were derived from individually calculated doses and dosing intervals in order to achieve, at steady state, a caffeine mean plasma concentration of 11 mg/l with a minimum of 7.5 mg/l and a maximum of 14.5 mg/l. We suggest dosing intervals for infants before 1 month, 1-2 months, 2-4 months and after 4 months to be equal to 24, 12, 8 and 6 h, respectively. The individual recommended dose varies from 2 to 10 mg/kg (as caffeine base) making caffeine monitoring mandatory in infants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191817     DOI: 10.1159/000457700

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  10 in total

1.  Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates.

Authors:  Sandrine Micallef; Billy Amzal; Véronique Bach; Karen Chardon; Pierre Tourneux; Frédéric Y Bois
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.

Authors:  C Cazeneuve; G Pons; E Rey; J M Treluyer; T Cresteil; G Thiroux; P D'Athis; G Olive
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

7.  Effect of pregnandiol on caffeine metabolism in female rats.

Authors:  T Bienvenu; G Pons; E Rey; G Thiroux; G Olive
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

Review 8.  Cardiorespiratory events in preterm infants: interventions and consequences.

Authors:  J M Di Fiore; C F Poets; E Gauda; R J Martin; P MacFarlane
Journal:  J Perinatol       Date:  2015-11-19       Impact factor: 2.521

Review 9.  Caffeine citrate: a review of its use in apnoea of prematurity.

Authors:  A M Comer; C M Perry; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

10.  HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure.

Authors:  Rosa Del Carmen Lopez-Sanchez; Victor Javier Lara-Diaz; Alejandro Aranda-Gutierrez; Jorge A Martinez-Cardona; Jose A Hernandez
Journal:  J Anal Methods Chem       Date:  2018-08-12       Impact factor: 2.193

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.